Biotech unicorn Moderna Therapeutics baffled its peers last month when it raised $500 million in a seventh round of venture financing. How, the question went, did the company sell investors on a $7.5 billion valuation despite outstanding questions about its science?
STAT obtained Moderna’s investor slide deck, one in which the company predicts billion-dollar futures for drugs only tested in mice and argues its vaccines business can bring in $15 billion in annual revenue.
About the Author Reprints
I did not find the full slide deck as mentioned in the article. Please share if you have it.
The full deck is embedded at the bottom of the article.
Pat Skerrett
STAT
Sounds like investors are getting either stupid or they have too much capital to throw away. Investing on a dec of slide which is 100000% based upon assumptions, not science and data.